Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AD-209 by Addpharma for Idiopathic (Essential) Hypertension: Likelihood of Approval
AD-209 is under clinical development by Addpharma and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData, Phase...
Data Insights
AD-209 by Addpharma for Idiopathic (Essential) Hypertension: Likelihood of Approval
AD-209 is under clinical development by Addpharma and currently in Phase II for Idiopathic (Essential) Hypertension. According to GlobalData, Phase...